At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 576 enrolled
Drug / intervention
liraglutide +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Effect on Glycemic Control of Liraglutide in Combination With Rosiglitazone Plus Metformin Versus Rosiglitazone Plus Metformin in Subjects With Type 2 Diabetes
In Brief
A Phase 3 clinical trial evaluating liraglutide, rosiglitazone, and 1 other intervention for Diabetes and Diabetes Mellitus, Type 2. Completed, enrolled 576 participants across 89 sites in 2 countries.
Detailed Summary
This trial is conducted in the United States of America (USA) and Canada. This trial is designed to show the effect of treatment with liraglutide when added to existing rosiglitazone and metformin combination therapy and to compare it with the effects of therapy with rosiglitazone and metformin alone.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes, Diabetes Mellitus, Type 2
CountriesCanada, United States
Collaborators--
Timeline
Phase 3CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartMay 2006
First PostedJun 2006
Primary CompletionAug 2007
TodayJul 2026
First PostedJun 2, 2006
Enrollment StartMay 1, 2006
Primary CompletionAug 1, 2007
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 20.1 years ago
Interventions
liraglutidedrug
rosiglitazonedrug
metformindrug